Skip to main content
Equibles
ABOS logo

ABOS · Acumen Pharmaceuticals, Inc. · Metrics

Track ABOS — free

Use ABOS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.94 -0.22 (-6.96%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, management has concluded that substantial doubt exists regarding our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$229.97M
Shares
72.32M

ABOS metrics

58 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.16
Market cap
$229.97M

Price action

20 metrics
Price change (1W)
+8.9%
Price change (30D)
+30.9%
Price change (3M)
+47.9%
Price change (6M)
-3.9%
Price change (YTD)
+50.7%
Price change (1Y)
+130.4%
Trailing year
Price change (5Y)
-79.6%
52-week high
$3.37
52-week low
$1.23
Change from 52-week high
-5.6%
Change from 52-week low
+158.5%
Annualized volatility
85.0%
Annualized volatility (3M)
72.6%
Beta
1.9
RSI (14D)
67.6
Price vs SMA 50
+23.0%
Price vs SMA 200
+30.2%
Avg volume (3M)
465,764
Relative volume
0.7
Average dollar volume
$1.16M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
72.32M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
4.0
reciprocal yield 24.9%
FCF yield
-39.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-45.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$105.42M
Net income (TTM)
−$105.04M
Trailing 12 months
Diluted EPS (TTM)
$-1.62
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-44.36

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+19.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-183.4%
Return on assets
-90.5%
Debt / equity
0.6
Current ratio
2.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$91.79M
Quick ratio
2.5
Interest coverage
-24.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$78.63M
Latest balance sheet
Cash & equivalents
$59.44M
Total assets
$116.01M
Total debt
$31.57M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$91.79M
Capital expenditures (TTM)
$0
R&D (TTM)
$86.79M
SG&A (TTM)
—
Stock compensation (TTM)
$9.80M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
96
13F filer change QoQ
+11
Institutional ownership
66.3%

Short interest

3 metrics
Short interest
4.5%
Latest settlement · 10.4 days to cover
Days to cover
10.4d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$75,240
Insider-sentiment score
46 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1576885 CUSIP 00509G209 13F (30d) 70 filings 70 filers Visit website Investor relations